Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer
Portfolio Pulse from
Candel Therapeutics Inc (NASDAQ:CADL) announced positive Phase 3 trial results for its immunotherapy CAN-2409, showing significant improvement in disease-free survival for localized prostate cancer patients.
December 11, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics' CAN-2409 showed a 14.5% improvement in disease-free survival in a Phase 3 trial for localized prostate cancer, reducing recurrence risk and improving survival rates.
The positive Phase 3 results for CAN-2409 are likely to boost investor confidence in Candel Therapeutics, as the drug shows significant improvement in disease-free survival for prostate cancer patients. This could lead to increased interest and potential stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100